drugset / Trial / NCT00887406

Study of GSK961081 in Healthy Volunteer Subjects

NCT00887406

Phase 1 Completed 46 enrolled Theravance Biopharma GlaxoSmithKline · collab
RandomizedCrossoverDouble-blindTreatment

Summary

GSK961081 is a new long-acting bronchodilator being developed for the treatment of chronic obstructive pulmonary disease (COPD). This study is the first clinical study in humans. The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK961081 in healthy male subjects.

Timeline

Start
2005-11-07
Primary completion
2006-10-04
Completion
2006-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Batefenterol Small molecule 3 ug Other
Subject Batefenterol Small molecule 15 ug Other
Subject Batefenterol Small molecule 50 ug Other
Subject Batefenterol Small molecule 100 ug Other
Subject Batefenterol Small molecule 200 ug Other
Subject Batefenterol Small molecule 300 ug Other